Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Day One Biopharmaceuticals Inc shares valued at $131,877 were sold by Ramasastry Saira on Jun 21 ’24. At $13.19 per share, Ramasastry Saira sold 10,000 shares. The insider’s holdings dropped to 40,485 shares worth approximately $0.56 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Blackman Samuel C. sold 30,000 shares, netting a total of over 378,588 in proceeds. Following the sale of shares at $12.62 each, the insider now holds 1,141,081 shares.
Before that, Bender Jeremy had sold 7,873 shares from its account. In a trade valued at $126,588, the CHIEF EXECUTIVE OFFICER traded Day One Biopharmaceuticals Inc shares for $16.08 each. Upon closing the transaction, the insider’s holdings decreased to 7,873 shares, worth approximately $9.05 million.
As published in a research note from Needham on April 24, 2024, Day One Biopharmaceuticals Inc [DAWN] has been retained to a Buy and the price target has been revised to $33. Analysts at BofA Securities downgraded the stock from ‘”a Buy”‘ to ‘”an Underperform”‘ outlook in a report released in late April. As of February 08, 2023, CapitalOne has initiated its “an Overweight” rating for DAWN. Earlier on February 03, 2023, Oppenheimer initiated its rating. Their recommendation was “a Perform” for DAWN stock.
Analyzing DAWN Stock Performance
During the last five days, there has been a surge of approximately 5.41%. Over the course of the year, Day One Biopharmaceuticals Inc shares have dropped approximately -5.27%. Shares of the company reached a 52-week high of $18.07 on 05/01/24 and a 52-week low of $11.94 on 06/17/24. A 50-day SMA is recorded $14.65, while a 200-day SMA reached $13.86. Nevertheless, trading volume fell to 1.08 million shares from 0.72 million shares the previous day.
Support And Resistance Levels for Day One Biopharmaceuticals Inc (DAWN)
According to the 24-hour chart, there is a support level at 13.30, which, if violated, would cause prices to drop to 12.76. In the upper region, resistance lies at 14.15. The next price resistance is at 14.46. RSI (Relative Strength Index) is 52.05 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.50, which suggests the price will decrease in the coming days. Percent R is at 9.57%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.
Which companies own the most shares of Day One Biopharmaceuticals Inc (DAWN)?
On December 15, 2022, H.C. Wainwright assigned a price target of “a Buy” to the stock and initiated coverage with a $35.
